Health Technology Assessment Dossier Strategist

Market access and health economics teams preparing submissions to payer bodies such as NICE (UK), HAS (France), G-BA (Germany), or ICER (US) use this agent to structure the HTA dossier, anticipate evidence gaps relative to the comparator, and develop the value story before pivotal trial data is locked.